Meeting
2013 ASCO Annual Meeting
Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
Authors
Lee Steven Schwartzberg
ACORN Research and The West Clinic, Memphis, TN
Lee Steven Schwartzberg , Kurt W. Tauer , Robert C. Hermann , Petros G. Nikolinakos , Arthur C. Houts
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT101388647
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS659)
DOI
10.1200/jco.2013.31.15_suppl.tps659
Abstract #
TPS659
Poster Bd #
16B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
First Author: Lee Steven Schwartzberg
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao
Poster
2011 ASCO Annual Meeting
Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial.
First Author: J. D. Zubkus
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey